VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis (VICTOR)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00876577 |
Recruitment Status
:
Completed
First Posted
: April 6, 2009
Last Update Posted
: September 10, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Chronic Bronchitis Disease Exacerbation | Drug: Moxifloxacin (Avelox, BAY12-8039) |
Study Type : | Observational |
Actual Enrollment : | 1206 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | VICTOR - Avelox® i.v. in Acute Exacerbations of Chronic Bronchitis |
Study Start Date : | May 2009 |
Actual Primary Completion Date : | March 2011 |
Actual Study Completion Date : | March 2011 |
Group/Cohort | Intervention/treatment |
---|---|
Group 1 |
Drug: Moxifloxacin (Avelox, BAY12-8039)
Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
|
- clinical cure rate:clinical cure was defined as disappearance of acute signs and symptoms [ Time Frame: up to 21 days ]
- Time to cure: time when symptoms are disappeared after Moxifloxacin treatment [ Time Frame: up to 21 days ]
- Improvement time: time when patients feel improvemen [ Time Frame: up to 21 days ]
- Time of patients recover from fever [ Time Frame: up to 21 days ]
- Clinical efficacy rate of Moxifloxacin [ Time Frame: up to 21 days ]
Biospecimen Retention: None Retained

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients at least 18 years of age with a diagnosis of AECB treated with Moxifloxacin injection with/without sequential tablet treatment
Exclusion Criteria:
- Exclusion criteria must be read in conjunction with the local product information

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00876577
China | |
Many Locations, China |
Study Director: | Bayer Study Director | Bayer |
Additional Information:
Responsible Party: | Medical Director, Bayer Healthcare AG |
ClinicalTrials.gov Identifier: | NCT00876577 History of Changes |
Other Study ID Numbers: |
14495 AX0810CN ( Other Identifier: Company internal ) |
First Posted: | April 6, 2009 Key Record Dates |
Last Update Posted: | September 10, 2012 |
Last Verified: | September 2012 |
Keywords provided by Bayer:
Acute Exacerbations of Chronic Bronchitis Avelox Bronchitis |
Additional relevant MeSH terms:
Bronchitis Bronchitis, Chronic Acute Disease Disease Progression Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Tract Infections Disease Attributes Pathologic Processes Pulmonary Disease, Chronic Obstructive Moxifloxacin Norgestimate, ethinyl estradiol drug combination |
Anti-Bacterial Agents Anti-Infective Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Contraceptives, Oral, Combined Contraceptives, Oral Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents Physiological Effects of Drugs |